openPR Logo
Press release

TMS a New Hope for Depression and Addiction Treatment

09-01-2021 02:53 PM CET | Health & Medicine

Press release from: Mind Brain Institute

Latest Treatment for Depression

Latest Treatment for Depression

The Mind-Brain Institute introduces you to the effective, non-invasive, and FDA- approved, treatment of the health issues like Depression, smoking, Anxiety, critical addiction as well as Obsessive-Compulsive Disorder or OCD.
Founder of the Mind Brain Institute or Dr. Anuranjan Bist, who is also a psychiatrist is having experience of long 16 years in this field and has brought out some technological-breakthrough in order to treat Major Depression, anxiety, OCD PTSD & various similar other diseases.
Their institute has introduced highly effective & FDA-approved, non-invasive treatment for patients who have been suffering from mental disorders, OCD, Depression, bad addiction and smoking. There are not many side effects are associated with this kind of treatment & this can be performed comfortably by the experts of MindBrain Institute. Apart from that, you will get fully optimized psychiatric facilities under cutting-edge treatment options.
How TMS is effective?
TMS or in other words Transcranial magnetic stimulation is the non-invasive and FDA-approved brain stimulation technique is very helpful for the treatment of certain diseases linked with anxiety, addiction, OCD, or any sort of disorder.
Is it helpful?
With the help of a doctor, the mind circuits which are involved with a certain types of brain disorders or additional related emotions can turn off or turn on those circuits linked with the disorders to stimulate under the magnetic field.
For future emotional disorders, anxiety, addiction like smoking and other OCD conditions, it is the best method for your treatment. It is non-invasive & very safe. Only at the start of the treatment, you may feel a little amount of headache that can be cured with normal health medicines. But after 2-3 sessions of this treatment, the headache will not be there.
How MindBrain is using it to treat people?
We are using very powerful magnets to stimulate those areas of the brain that is carrying the signals from one part of the brain to the other one that is concerned with emotions to make them stronger and resilient. Therefore, that circuit will not get effective and certain anxiety or sudden depression does not come in.
For Detail Visit
A-1/288 First Floor Safdarjung Enclave, New Delhi 110029
Mon - Sat : 9:00 AM - 7:00 PM
+91-9971774999 011-47063551

A-1/288 First Floor Safdarjung Enclave, New Delhi 110029

Mind Brain Institute is one of the best mental health clinics that provide TMS therapy solutions for treating a wide range of mental problems. The clinic’s TMS therapy is a highly-effective solution for all forms of anxiety, depression, and many others.

This release was published on openPR.

Permanent link to this press release:

Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release TMS a New Hope for Depression and Addiction Treatment here

News-ID: 2375712 • Views: 656

More Releases for Depression

Increase in the prevalence of anxiety disorders and depression is bolstering the …
The research report "Global Anxiety Disorders and Depression Treatment Market: By Product Type (MAOIs (Monoamine Oxidase inhibitors), Atypical Antipsychotics, Benzodiazepines, Anticonvulsants, Beta-Blockers, SRIs (Selective Serotonin Reuptake Inhibitors), SNRIs (Serotonin-Norepinephrine Reuptake Inhibitors), TeCAs (Tetracyclic Antidepressants), TCAs (Tricyclic Antidepressants), Others), By Distribution Channel (Hospital Pharmacies, Online Pharmacies, Others), and Geography- Global/Region/Country Forecast to 2028." The global anxiety disorders and depression treatment market size was valued at USD 8.2 Bn in the year
Depression Treatment Device Market: Information by Product Type (Light Therapies …
Depression is characterized by multiple mental health challenges that involve a lack of positivity, suicidal thoughts, insomnia, anxiety, loss of appetite, and sadness. Depression is caused by a combination of biological, genetic, environmental, and psychological factors. Globally, the prevalence of depression is increasing at an alarming rate. About 300 million people of all ages suffered from depression and the suicide rate rose to about 8,00,000 individuals in 2018. As per
Depression Cannot Hit A Moving Target
Cottonwood Heights, Utah, Mar 12, 2020 -- Depression can't hit a moving target. That was a phrase to live by for Chelsea Hansen. She was full of life and love, and she had big goals. But soon she was to discover that life doesn't turn out the way she planned. Behind the Fake Smile is a fictional book based on real-life experiences. It's the story of how Chelsea navigates a world
Depression Drugs Market: Increase in Cases of Depression to Boost Market Growth
Transparency Market Research (TMR) has published a new report titled, “Depression Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2018–2026”. According to the report, the global depression drugs market was valued at US$ 6,500 Mn in 2017 and is anticipated to decline at a CAGR of 2% from 2018 to 2026. The report suggests that rise in incidence of major depression disorders is projected to drive
Depression Therapeutics Market Forecast till 2025
Antidepressants are used to treat a wide range of mental disorders, including depression, anxiety, and major depressive disorder. Certain neurotransmitters in the brain exist in chemical form such as dopamine and serotonin, which are responsible for maintaining emotional balance such as mood and behavior. Antidepressants cover a wide range of drug categories, including selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants
Depression Drug Market: Global Depression Drug Forecast Will Reach $16.8 billion …
Zion Market Research has published a new report titled “Depression Drug (Benzodiazepines, SNRIs, TCAs, TeCAs, Atypical Antipsychotics, Monoamine Oxidase inhibitors and Others) Market: Global Industry Perspective, Comprehensive Analysis and Forecast, 2014 – 2020” According to the report, the global depression drug market was valued at USD 14.51 billion in 2014 and is expected to generate revenue of USD 16.8 billion by end of 2020, growing at a CAGR of 2.50%